FDA Documentation Translation Services

The Agency Reads the English Version and Nothing Else

Every FDA center works from an English record. 21 CFR 314.50(g) states it without ambiguity for drug applications: any part of the submission written in another language arrives with an English translation of a foreign language study report plus a certification of accuracy, and the original stays in the file. Device filings carry the same expectation under Part 807. A 510(k) that shows up with a Japanese bench test report or an untranslated Spanish clinical summary sitting in an appendix comes back through the Refuse to Accept checklist before anyone assesses substantial equivalence. That is not a scientific setback. It is a calendar one, and calendars are where product launches quietly die.

Jurilingua built this desk around that single fact. FDA documentation translation is not medical writing rendered into another language; it is a controlled document exercise where a specification limit carried across loosely, a unit conversion done from memory, or one sentence in a deviation report that softens what actually happened will generate a question the agency asks you about for the next eighteen months. Filings go to translators who studied the underlying science before they ever studied translation: pharmacologists, biomedical engineers, analytical chemists, toxicologists, people who know what a coefficient of variation is doing in a validation table. A second specialist then reads the full package against the source before release. We have run submissions that way since 1984 and have yet to find a reason to loosen it.

What a regulatory affairs lead gets back is a package that can be handed to a reviewer without a covering apology. It sits inside the wider compliance translation practice we operate for regulated industries, tuned here to the agency's particular rhythms: the pre-submission meeting, the information request with a short fuse, the inspection response due in fifteen working days whether or not half the evidence is in Mandarin.

From a 510(k) to a Biologics License: The Filings We Carry

On the device side the bench handles the whole CDRH sequence. Traditional, abbreviated and special 510(k) submission translation, De Novo requests, PMA translation and the supplements that follow approval, 513(g) requests, IDE applications and the pre-submission packages that shape all of them. What actually needs rendering is rarely the cover letter. It is the bench testing protocols and reports, the biocompatibility evaluations, the sterilization and shelf life validations, the software documentation, the risk management file and the clinical evaluation report that a European manufacturer assembled in its own language for an MDR technical file and now has to present to an American reviewer who works from a different framework entirely.

On the drug and biologic side the desk covers IND and NDA translation, ANDA submissions for generics, BLA dossiers and drug master file translation across Types II through V. Work arrives sorted by eCTD module translation: Module 3 chemistry, manufacturing and controls from a plant in Zhejiang or Lombardy, Module 4 nonclinical study reports written by a contract lab in Japan, Module 5 clinical study reports and bioequivalence data from sites in India, Poland or Brazil. Certificate of analysis translation, stability protocols, method validation reports and specification sheets travel with them, because the agency will compare the number in the specification to the number in the release record and expect them to agree.

Foreign studies deserve their own mention. When a sponsor relies on a clinical study not conducted under an IND, the agency looks for evidence the study met the standards in 21 CFR 312.120, and that evidence sits in ethics committee approvals, investigator qualifications and protocol amendments that were never written in English. Getting those documents rendered faithfully, including the parts that are inconvenient, is what separates a submission that survives review from one that invites a data integrity question. The commercial paper behind those studies sits with a different team; the science comes here.

Labeling and IFU: The Words That Reach a Clinician at Three in the Morning

Device labeling translation and instructions for use translation carry a burden most regulatory documents do not: someone will act on them under pressure. An IFU translation that renders a contraindication as a caution, or blurs the difference between rinse and flush, produces a use error, and use errors produce adverse event reports, which produce further correspondence with the agency. Part 801 governs how device labeling must read for the American market, Part 201 does the same for drug labeling, and neither is satisfied by a competent word for word transfer of the manufacturer's home market text. The content has to be restructured into US expectations while remaining faithful to the cleared or approved claims.

The desk handles package inserts, carton and container labels, patient package inserts, medication guides, IFU booklets, quick reference guides, symbol glossaries under 801.15(c), UDI data elements and the labeling supplements that follow every change. Terminology is locked in a client specific base so the phrase used in the Module 3 specification, the phrase printed on the carton and the phrase appearing in a field safety notice three years later are the same phrase. Manufacturers with a dozen products and four source languages find that consistency is worth more than any single translation, because inconsistency is what an investigator notices first.

Supplier documentation feeds the same file. Component specifications, sterilization contracts and quality agreements written by an overseas manufacturing partner have to line up with what the labeling claims, which is why this desk works in step with the team that renders production contracts. When the paperwork agrees with itself across the supply chain, the submission reads like one organization speaking. When it does not, the reviewer asks why.

Form 483 Season: Translating Against a Fifteen Day Clock

An investigator leaves a foreign site, hands over a Form 483, and a countdown begins. Respond within fifteen working days and your reply is considered before the agency decides what comes next. Miss it, or file a response built on evidence nobody at the agency can read, and the file moves toward a warning letter, an Official Action Indicated classification, an import alert or detention without physical examination. Form 483 response translation and warning letter response translation are therefore not ordinary jobs. They are deadline work where the deadline is set by someone else and does not move.

The material behind a strong response is almost always in the site's working language: executed batch records, deviation investigations, CAPA files, complaint handling logs, training records, equipment qualification and cleaning validation reports, environmental monitoring data, supplier qualification files and the annual product review. FDA inspection document translation means getting all of that into English fast enough to be useful and accurately enough to be defensible, including the entries that do not flatter the site. We do not smooth anything. A response that reads better than the underlying record is a liability, not an asset, and experienced regulatory counsel spots the gap immediately.

Rush handling on this desk keeps the two reader rule intact rather than trading it away for hours. Files can be split by document family, staged in daily batches so counsel drafts while translation continues, and delivered with running commentary on anything ambiguous in the source. Adverse event report translation runs on a similar footing, since MedWatch and periodic safety reporting obligations do not pause while a foreign affiliate finds someone bilingual. Where the underlying quality system documents need rendering as well, they belong on the procedures desk linked below, and the audit findings that triggered the whole sequence run through our inspection and audit reporting team.

The Certification Page, and Everything Wrapped Around It

Certified translation for FDA submission has a specific shape. The package carries a signed statement identifying the document, the source and target languages, the date, the translator or the company attesting to completeness and accuracy, and credentials available on request. The original stays bound with the English version so a reviewer can jump between them. Notarization is added when a client's internal policy or a foreign authority asks for it. Nothing about this is decorative: the certification is the agency's assurance that the English text it evaluates corresponds to the record the site actually kept, and our approach to that attestation is set out on the page covering certification.

Format matters nearly as much. Submissions go out as text searchable PDFs with the bookmark and hyperlink structure eCTD publishing expects, tables rebuilt rather than flattened into images, page numbering aligned so a reviewer moving from a translated study report to its source lands on the same content, and figures relabeled with their captions rendered. Signature blocks, stamps and handwritten marginalia in a batch record get described in place rather than dropped, because a handwritten correction is often the exact thing an investigator was asking about. Files that will live inside a validated system are prepared with 21 CFR Part 11 realities in mind, so nothing has to be rebuilt after delivery.

Behind the finished page sits a process a client can audit. Assignment by subject matter, a terminology pass before drafting begins, translation, independent review by a second specialist, then a regulatory formatting check. It is described in more detail in our working method, and the professional standing that supports it is documented on the memberships page: corporate accreditation with the ATA, a seat inside GALA, plus a place in the North American Translation Alliance. Those affiliations matter chiefly because they put us inside the peer structures that keep this kind of work honest.

Who Sends Us Regulatory Files

Sponsors preparing a first US filing send whole dossiers, often assembled over years in two or three languages, and want a single English record with consistent terminology throughout. Device manufacturers entering the American market send technical files built for another regulator and need them recast for CDRH. Contract research organizations send study reports on rolling deadlines. Regulatory consultancies send client work under their own letterhead requirements. FDA counsel at US law firms send inspection material and enforcement correspondence, usually with a date circled in red. Importers and distributors send supplier documentation when a shipment is sitting at the port. Public health bodies and agency contractors route work through the same bench, alongside the wider public sector language work we support.

Every one of them gets the same handling. Nothing sits unencrypted, in transit or at rest. Read rights reach the named project team and stop there, and an NDA is executed up front wherever your internal rules ask for one. Unpublished clinical data and manufacturing know how are among the most commercially valuable documents a company owns, and they are treated accordingly. Each client keeps a private translation memory and terminology base, which means the second submission costs less than the first, the labeling matches the dossier, and the response to an observation two years from now uses the vocabulary the agency already accepted. You can see who does the work on the page covering the specialists behind these files.

Cost is calculated on word volume, adjusted for the pair involved and for how dense the material runs, with memory reuse cutting the price of anything derived from work already done. How that number gets built is broken down on our rates page. Send the documents and a costed quote is back with you the same hour, carrying a committed delivery date rather than an estimate. Life science clients rate this desk 4.8 out of 5 across four decades of filings, which is the figure we would check first if we were the ones hiring.

The Source Languages a US Filing Usually Arrives In

Regulatory files follow manufacturing and research: Chinese for API plants and device assembly, German for technical files built to European rules, Japanese for bench and nonclinical reporting, Hindi alongside Indian bioequivalence work, Korean for biosimilar sponsors, Spanish and Italian across contract manufacturing. The roster runs past eighty, and every one of them lands in English here. See the full language directory.

Where the US Regulatory Work Actually Sits

Submissions come to this desk from the clusters that build them: Boston and its biotech corridor, Philadelphia pharma, San Diego device and diagnostics houses, the Minneapolis medtech belt, Raleigh and its CRO population, northern New Jersey, Indianapolis, San Francisco biologics, Salt Lake City, Chicago, and Washington DC, where the agency counsel and the consultancies keep their offices. Distance is irrelevant to the delivery date.